Form 4: Vistagen Therapeutics Director Joanne Curley Granted Stock Options

Director Joanne Curley received 12,500 stock options in Vistagen Therapeutics, Inc.

Summary

• Joanne Curley, a director of Vistagen Therapeutics, Inc., was granted 12,500 stock options on March 4, 2024.
• The options have an exercise price of $4.85.
• The options vest in twelve equal monthly installments starting on the grant date and expire on March 4, 2034.
• The grant was made under the company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended.
• A power of attorney was executed on September 8, 2023, granting Shawn K. Singh and Cynthia Anderson the authority to file Forms 3, 4, and 5 on behalf of Joanne Curley.

Sentiment

Score: 6

Explanation: The document is neutral, simply reporting a standard stock option grant. It doesn't contain any information that would significantly sway investor sentiment positively or negatively.

Positives

• The granting of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across the biotechnology industry.
• Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their compensation packages for directors and executives.
• The vesting schedule of twelve equal monthly installments is fairly standard, aligning with typical industry practices for incentivizing long-term performance.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates